Enimmune corporation reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 92.09 million compared to TWD 50.71 million a year ago. Net loss was TWD 155.79 million compared to TWD 13.5 million a year ago.

Basic loss per share from continuing operations was TWD 2.52 compared to TWD 0.22 a year ago. Diluted loss per share from continuing operations was TWD 2.52 compared to TWD 0.22 a year ago.